Tumor Biology

, Volume 36, Issue 3, pp 1511–1518 | Cite as

Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET

  • Chengjun Sui
  • Feng Xu
  • Weifeng Shen
  • Li Geng
  • Feng Xie
  • Binghua Dai
  • Jiongjiong Lu
  • Minfeng Zhang
  • Jiamei Yang
Research Article


Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world with poor prognosis. Here, we investigated the role of microRNA 218 (miR-218) in regulating human HCC development. Quantitative PCR (qPCR) was used to compare the expression levels of miR-218 between eight HCC and a normal liver cell lines, as well as nine primary HCC tissues and adjacent non-carcinoma tissues. HCC cell lines MHCC97L and Huh7 were transfected with lentiviral vector of miR-218 mimics. The effect of miR-218 overexpression on cancer cell growth, both in vitro and in vivo, as well as cancer cell invasion was examined. A bioinformatic method was used to predict the binding of miR-218 to RET proto-oncogene (RET). Small interfering RNA (SiRNA)-mediated genetic knock-down of RET was performed in MHCC97L and Huh7 cells, and its modulatory effect on miR-218-mediated HCC development was examined. miR-218 was found to be downregulated in HCC cell lines and primary HCC tissues. Overexpression of miR-218 in MHCC97L or Huh7 cells resulted in significant decrease in cell proliferation and invasion capability. Overexpression of miR-218 also reduced the tumor growth of xenografted Huh7 cells in vivo. The expression of endogenous RET was found to be upregulated by miR-218, and siRNA-induced RET downregulation resulted in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) upregulation and reversal of the inhibitory effect of miR-218 upregulation on HCC proliferation. Our results indicate that miR-218 modulates HCC development, and this effect may be through RET and PTEN.


miR-218 RET Hepatocellular carcinoma PTEN 


Authors’ contribution

This study was designed by Jiamei Yang. Acquisition of data was performed by Chengjun Sui, Feng Xu, Jiongjiong Lu, and Minfeng Zhang. Weifeng Shen, Li Geng, Feng Xie, and Binghua Dai analyzed and interpreted the results. The manuscript was drafted by Chengjun Sui. Revision was done by Chengjun Sui and Jiamei Yang. Author E provided statistical advice.


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010;27:2893–917.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–69.CrossRefPubMedGoogle Scholar
  4. 4.
    Worns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302–309.CrossRefPubMedGoogle Scholar
  5. 5.
    Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, Frilling A: Liver transplantation for neuroendocrine tumour liver metastases. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014Google Scholar
  6. 6.
    Page AJ, Weiss MJ, Pawlik TM: Surgical management of noncolorectal cancer liver metastases. Cancer 2014.Google Scholar
  7. 7.
    Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005;15:563–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310:1817–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Greve TS, Judson RL, Blelloch R. MicroRNA control of mouse and human pluripotent stem cell behavior. Annu Rev Cell Dev Biol. 2013;29:213–39.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113:6207–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 1845;2014:255–65.Google Scholar
  13. 13.
    Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Ishiguro H, Kimura M, Takeyama H. Role of microRNAs in gastric cancer. World J Gastroenterol. 2014;20:5694–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Seton-Rogers S. Tumour suppressors: hippo promotes microRNA processing. Nat Rev Cancer. 2014;14:216–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 2013;73:473–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014;20:6906–11.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78.CrossRefPubMedGoogle Scholar
  19. 19.
    He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, et al. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2012;18:1491–8.PubMedCentralGoogle Scholar
  20. 20.
    Li J, Ping Z, Ning H. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012;13:16053–64.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 1996;381:785–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–4.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96:143–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001;12:361–73.CrossRefPubMedGoogle Scholar
  26. 26.
    Yin L, Puliti A, Bonora E, Evangelisti C, Conti V, Tong WM, et al. C620r mutation of the murine RET proto-oncogene: loss of function effect in homozygotes and possible gain of function effect in heterozygotes. Int J Cancer. 2007;121:292–300.CrossRefPubMedGoogle Scholar
  27. 27.
    Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19.CrossRefPubMedGoogle Scholar
  28. 28.
    Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett. 2005;10:479–98.PubMedGoogle Scholar
  29. 29.
    Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007;28:879–87.CrossRefPubMedGoogle Scholar
  31. 31.
    Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, et al. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep. 2010;23:1593–600.PubMedGoogle Scholar
  33. 33.
    Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. MicroRNA gene expression profile of hepatitis c virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang LS, Liang WB, Gao LB, Li HY, Li LJ, Chen PY, et al. Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 2012;31:761–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Li J, Ping Z, Ning H. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012;13:16053–64.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Chengjun Sui
    • 1
  • Feng Xu
    • 1
  • Weifeng Shen
    • 1
  • Li Geng
    • 1
  • Feng Xie
    • 1
  • Binghua Dai
    • 1
  • Jiongjiong Lu
    • 1
  • Minfeng Zhang
    • 1
  • Jiamei Yang
    • 1
  1. 1.Department of Special Medical Care and Liver Transplantation, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations